查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018615

獸用抗感染劑市場：2026-2032年全球市場預測（依產品類型、給藥途徑、動物類型、通路及應用分類）

Veterinary Anti-infectives Market by Product Type, Route Of Administration, Animal Type, Distribution Channel, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，獸用抗感染劑市場價值將達到 48.1 億美元，到 2026 年將成長至 54 億美元，到 2032 年將達到 109 億美元，複合年成長率為 12.39%。

主要市場統計數據
基準年 2025 48.1億美元
預計年份：2026年 54億美元
預測年份：2032年 109億美元
複合年成長率 (%) 12.39%

本文簡要概述了不斷發展的獸用抗感染劑產業，其發展受到臨床需求、管理壓力和策略性商業性需求的驅動。

獸用抗感染劑產業正處於一個轉折點，科學進步、動物健康優先事項的轉變以及不斷變化的監管和貿易環境正在重塑產品的研發、分銷和使用。本文簡要概述了影響伴侶動物、牲畜、家禽和水產養殖中抗生素、抗真菌藥物和驅蟲藥使用的關鍵因素。本文著重分析臨床需求、合理用藥要求和商業性現實之間的相互作用，為深入分析市場動態和戰略意義奠定了基礎。

確定正在重塑獸用抗感染劑，包括診斷、合理使用、供應彈性以及數位分銷的動態。

在科學創新、監管加強和相關人員期望轉變的驅動下，獸用抗感染劑領域正經歷變革。診斷技術的進步加速了從經驗性治療到標靶治療的轉變，使獸醫能夠更精準地選擇藥物，同時減少不必要的用藥。同時，對合理使用抗生素的監管力道也在加大，監管機構和採購方要求提供更清晰的合理用藥證據和風險緩解策略，這正在影響藥物目錄的製定和製劑的選擇。

分析關稅和貿易政策的變化如何影響整個價值鏈的供應鏈決策、定價策略和風險緩解方法。

關稅的引入和貿易政策的變化為獸用抗感染劑的商業環境帶來了新的複雜性。關稅調整正在影響製造地、採購決策和定價策略，促使生產商和經銷商重新評估其全球供應鏈。為此，許多企業正在探索近岸外包、雙重採購和庫存最佳化策略，以降低關稅相關成本波動帶來的風險，並維持關鍵治療藥物的供應。

從產品類型、給藥途徑、目標動物類型、分銷管道和應用背景等方面的詳細見解塑造了我們的產品策略。

細分市場層面的洞察揭示了不同產品類型、給藥途徑、動物類型、分銷管道和應用領域的發展趨勢，這些趨勢共同影響研發重點和市場策略。在各類產品中，抗生素仍佔據核心地位，但該類別內部的發展趨勢正在分化。Aminoglycosides、BETA-內醯胺類、Fluoroquinolones、大環內酯類、磺胺類藥物和四環黴素各自面臨不同的合理使用管理和監管方面的考慮，這影響標籤、停藥期和使用指南。抗真菌藥物，包括Azole和Polyenes，需要精細的製劑策略來平衡局部和全身給藥的療效和安全性。抗寄生蟲藥物，包括殺蟎劑、驅蟲劑和殺蟲劑，在研發過程中越來越注重抗藥性和環境影響，這推動了對新型化學物質及其與綜合蟲害管理（IPM）相容性的研究。

對全球主要地區的監管要求、分銷特點和市場准入考慮因素進行全面的區域分析。

區域趨勢在美洲、歐洲、中東和非洲以及亞太地區的監管要求、供應鏈設計和商業策略的發展中發揮著至關重要的作用。美洲的獸藥市場已趨於成熟，監理合規標準高，經銷網路完善。因此，製造商優先考慮證據的建立、標籤差異化和基於價值的契約，以適應採購和獸醫實踐模式。相較之下，歐洲、中東和非洲的情況則截然不同。歐洲部分地區對藥品管理和藥物安全檢測的要求非常嚴格，而該地區其他市場的監管能力則參差不齊，因此需要根據需求的成長情況制定靈活的打入市場策略。

檢驗決定感染疾病物組合領導地位和差異化的競爭定位、創新路徑和夥伴關係模式。

獸用抗感染劑的競爭格局由眾多參與企業所構成，包括成熟的製藥公司、專業的動物用藥品公司和新興的生物技術公司，每家公司在研發、生產和商業化的各個階段都奉行著各自獨特的策略。老字型大小企業憑藉其豐富的產品系列、監管經驗和全球分銷網路來維持市場地位，而規模較小的公司則往往專注於特定適應症、特殊配方或更快的研發週期來競爭。生物技術領域的參與企業企業和受託研究機構正在推動新型活性成分、標靶給藥系統和替代治療方法的創新，這些創新有望顛覆傳統的化療。

為產業領導者提供切實可行的優先建議，以加強供應鏈韌性、證據產生、管理誠信和商業性差異化。

產業領導者應採取一系列切實可行的措施，以平衡短期業務永續營運和長期策略優勢。首先，透過來源多元化、雙重採購策略以及嚴格的供應商品質審核來增強供應鏈韌性，從而降低關稅和貿易中斷的影響。其次，將診斷應用案例融入產品開發和市場定位，以支持標靶治療、減少不當使用，並強化能夠引起監管機構和買家共鳴的藥物管理主張。第三，增加對證據產生的投入，不僅包括註冊測試，還包括真實世界療效研究、抗藥性監測和藥物監測，從而全面證明藥物的長期安全性和價值。

採用多方面的調查方法，結合專家意見、監管審查和情境分析，並輔以透明的解釋，以得出可靠且檢驗的結論。

本分析的調查方法結合了定性專家訪談、二手文獻綜述以及監管指南和公開臨床證據的結構化整合。關鍵資訊來源包括對獸醫、監管專家、生產和供應鏈高管以及分銷合作夥伴的訪談，以了解不同物種和分銷管道的實際情況和決策標準。二級資訊來源包括關於抗菌素抗藥性的同行評審文獻、監管指南文件和行業出版物，以確保與普遍接受的臨床和政策框架保持一致。

最終整合凸顯了整合策略的必要性，該策略涵蓋管理、供應彈性、證據生成和個人化的商業性方法。

總之，獸用抗感染劑的格局正受到科學、監管和商業性因素複雜交互作用的影響而重塑，這需要產業相關人員採取綜合應對措施。對合理使用抗生素的需求以及診斷技術的進步正推動產品研發朝著精準應用和可靠證據的方向發展，而政策變化和關稅措施則促使企業建立更具韌性的供應鏈。依產品類型、給藥途徑、目標動物、分銷管道和應用場景進行細分，凸顯了統一策略的不足。相反，針對特定物種的需求、細微的區域監管差異以及管道特定趨勢，制定個人化最佳化方案至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 獸用抗感染劑市場：依產品類型分類

  • 抗生素
    • Aminoglycosides
    • BETA-內醯胺
    • Fluoroquinolones
    • 大環內酯類
    • 磺胺類藥物
    • 四環黴素
  • 抗真菌藥物
    • Azole
    • Polyenes
  • 驅蟲
    • 殺蟎劑
    • 抗寄生蟲藥物
    • 殺蟲劑

第9章 獸用抗感染劑市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服
    • 顆粒
    • 粉末
    • 懸浮液
    • 藥片
  • 外用
    • 奶油
    • 沾
    • 軟膏
    • 噴

第10章 獸用抗感染劑市場：依動物類型分類

  • 水產養殖
    • 魚
    • 蝦
  • 伴侶動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 山羊
    • 羊
    • 豬
  • 家禽
    • 雞
    • 火雞

第11章 獸用抗感染劑市場：依通路分類

  • 網路藥房
  • 零售藥房
  • 動物診所
  • 動物醫院

第12章 獸用抗感染劑市場：依應用分類

  • 為了預防
  • 治療

第13章 獸用抗感染劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 獸用抗感染劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 獸用抗感染劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國獸用抗感染劑市場

第17章：中國獸用抗感染劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ashish Life Science Private Limited
  • Bimeda Inc.
  • Biogenesis Bago SA
  • CH Boehringer Sohn AG & Co. KG
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Eco Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Intas Pharmaceuticals Ltd.
  • Krka, dd, Novo mesto
  • Kyoritsuseiyaku Corporation
  • LABORATORIO AVI-MEX
  • LABORATORIOS CALIER, SA
  • Merck KGaA
  • Neogen Corporation
  • Ourofino Group
  • Sequent Scientific Ltd.
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-2214614768CF

The Veterinary Anti-infectives Market was valued at USD 4.81 billion in 2025 and is projected to grow to USD 5.40 billion in 2026, with a CAGR of 12.39%, reaching USD 10.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.81 billion
Estimated Year [2026] USD 5.40 billion
Forecast Year [2032] USD 10.90 billion
CAGR (%) 12.39%

Concise orientation to the evolving veterinary anti-infectives sector setting context on clinical needs, stewardship pressures, and commercial imperatives shaping strategy

The veterinary anti-infectives sector is at an inflection point where scientific advances, shifting animal health priorities, and evolving regulatory and trade environments are reshaping how products are developed, distributed, and used. This introduction provides a concise orientation to the core drivers affecting antibiotic, antifungal, and antiparasitic therapies across companion animals, livestock, poultry, and aquaculture. It highlights the interplay between clinical need, stewardship imperatives, and commercial realities, setting the stage for deeper analysis of market dynamics and strategic implications.

As animal health systems adapt to pressures such as antimicrobial resistance concerns, heightened biosecurity standards, and changes in supply chains, stakeholders must reconcile short-term operational challenges with long-term investment decisions. Integrated approaches that combine clinical efficacy, safety, and responsible use are increasingly central to product positioning. Moreover, technological enablers-ranging from digital diagnostics to precision delivery systems-are altering the value proposition for new and existing therapies. Framing these forces up front ensures readers appreciate why cross-functional alignment, data-driven decision-making, and agile commercialization strategies are essential for sustaining growth and ensuring therapeutic relevance in a rapidly changing landscape.

Identification of the major transformative forces reshaping veterinary anti-infectives including diagnostics, stewardship, supply resilience, and digital distribution dynamics

The landscape for veterinary anti-infectives is experiencing transformative shifts driven by scientific innovation, regulatory tightening, and changes in stakeholder expectations. Advances in diagnostic capabilities are accelerating the move from empirical treatment toward targeted therapy, enabling veterinarians to select agents with greater precision while reducing unnecessary use. In parallel, there is intensified scrutiny on antimicrobial stewardship, with regulators and purchasers demanding clearer evidence of appropriate use and risk mitigation strategies, which in turn influences formulary decisions and prescribing behavior.

Concurrently, the supply chain is undergoing recalibration. Sourcing strategies that prioritize geographic diversity, quality assurance, and supplier transparency are becoming standard practices. Digital platforms and telemedicine are also expanding access to veterinary consultation and therapy management, creating new channels for distribution while raising questions about appropriate oversight. Private and public investment in novel modalities and formulation technologies continues to grow, but so does the need for robust post-market surveillance and lifecycle management. Collectively, these shifts are prompting manufacturers to rethink product development priorities, regulatory engagement, and commercial models to remain relevant and compliant in an environment that prizes both efficacy and responsible stewardship.

Analysis of how tariff changes and trade policy shifts are influencing supply chain decisions, pricing strategies, and risk mitigation approaches across the value chain

The introduction of tariffs and trade policy changes has added a new layer of complexity to the operational environment for veterinary anti-infectives. Tariff adjustments can influence manufacturing footprints, sourcing decisions, and pricing strategies, prompting manufacturers and distributors to reassess their global supply chains. In response, many organizations are examining nearshoring, dual-sourcing, and inventory optimization measures to mitigate exposure to tariff-related cost volatility and to preserve supply continuity for critical therapies.

These policy-driven shifts interact with existing regulatory and market pressures, affecting decisions related to contract manufacturing, inventory allocation, and route-to-market structuring. Companies with vertically integrated supply chains or diversified production locations are generally better positioned to absorb incremental tariff costs without passing the full burden onto end customers. Conversely, firms reliant on single-source imports or high-volume, low-margin product lines may face margin compression that requires strategic repricing, renegotiation of supplier terms, or adjusted channel incentives. In this context, scenario planning and tariff-impact modelling become essential tools for leaders seeking to protect access to essential anti-infective treatments while sustaining commercial viability and aligning stakeholder expectations.

Deep segmentation-driven insights across product types, administration routes, animal classes, distribution channels, and application contexts shaping product strategies

Segment-level insights reveal differentiated dynamics across product types, routes of administration, animal classes, distribution channels, and applications that together shape development priorities and go-to-market strategies. Within product type, antibiotics remain central but their internal trajectories diverge: aminoglycosides, beta-lactams, fluoroquinolones, macrolides, sulfonamides, and tetracyclines each face distinct stewardship and regulatory considerations that influence label claims, withdrawal periods, and usage guidelines. Antifungals, segmented into azoles and polyenes, demand nuanced formulation strategies to balance efficacy with safety in both topical and systemic applications. Antiparasitics-spanning acaricides, anthelmintics, and insecticides-are increasingly developed with resistance management and environmental impact in mind, guiding research toward novel chemistries and integrated pest management compatibility.

Route of administration further affects adoption and product development choices. Injectable options, whether intramuscular, intravenous, or subcutaneous, are often prioritized for acute care and hospitalized animals, while oral formulations-pellets, powders, suspensions, and tablets-are tailored for ease of dosing in herd management and companion care. Topical formats such as creams, dips, ointments, and sprays play a pivotal role in dermatological and ectoparasite management where localized exposure and rapid action are critical. Animal type segmentation differentiates clinical pathways and commercial approaches; aquaculture (fish and shrimp) requires water-stable and environmentally considerate chemistries, companion animals (cats and dogs) prioritize safety and owner-friendly dosing, livestock (cattle, goats, sheep, swine) emphasize withdrawal times and mass-administration practicality, and poultry (chicken and turkey) demand solutions that integrate into flock health protocols. Distribution channels shape access and commercial interaction: online pharmacies, retail pharmacies, veterinary clinics, and veterinary hospitals each present different regulatory touchpoints, margin structures, and customer engagement models. Lastly, the application lens-prophylactic versus therapeutic-drives product positioning, evidence requirements, and stakeholder communications, with prophylactic uses prompting additional scrutiny under stewardship frameworks and therapeutic indications necessitating robust clinical efficacy data.

Comprehensive regional analysis of regulatory expectations, distribution nuances, and market access considerations across major global territories

Regional dynamics play a pivotal role in shaping regulatory expectations, supply chain design, and commercial tactics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas present a mature veterinary market with high standards for regulatory compliance and established distribution networks; manufacturers therefore emphasize evidence generation, label differentiation, and value-based contracting to align with procurement and veterinary practice patterns. In contrast, the Europe, Middle East & Africa region is heterogeneous: parts of Europe demand rigorous stewardship and pharmacovigilance, while other markets in the broader region present variable regulatory capacity and growing demand that calls for adaptable market-entry strategies.

Asia-Pacific features diverse market maturities and rapid growth pockets, especially where livestock intensification and aquaculture expansion amplify demand for effective anti-infective solutions; however, this growth is accompanied by a pressing need for quality assurance and monitoring to mitigate resistance risks. Across all regions, trade policy variations, import controls, and locally mandated manufacturing or registration requirements can materially affect timelines and go-to-market choices. Consequently, regional strategies must balance global standardization with localized regulatory navigation, tailored evidence packages, and culturally informed engagement models with veterinarians, producers, and distributors.

Examination of competitive positioning, innovation pathways, and partnership models that determine leadership and differentiation in anti-infective portfolios

Competitive dynamics in veterinary anti-infectives are shaped by a mix of established pharmaceutical companies, specialized animal health players, and emerging biotech innovators, each pursuing distinct strategies across research, manufacturing, and commercialization. Established firms leverage broad portfolios, regulatory experience, and global distribution networks to maintain market presence, while smaller and mid-sized companies often compete on niche indications, specialized formulations, or faster development cycles. Biotech entrants and contract research organizations contribute innovation in novel active ingredients, targeted delivery systems, and alternative modalities that may disrupt traditional chemistries.

Partnerships and strategic alliances are increasingly common, enabling scale-up, access to proprietary technologies, or acceleration of registration pathways. Companies that invest in robust pharmacovigilance, resistance monitoring, and evidence generation are better equipped to meet evolving regulatory expectations and to support stewardship narratives with credible data. At the same time, internal capabilities in manufacturing quality, supply-chain risk management, and digital engagement-such as telehealth-enabled product support or data-driven dosing tools-differentiate market leaders. Overall, the competitive landscape rewards organizations that combine scientific rigor with operational resilience and compelling value propositions tailored to customer segments.

Practical and prioritized recommendations for industry leaders to strengthen supply resilience, evidence generation, stewardship alignment, and commercial differentiation

Industry leaders should pursue a set of actionable steps that balance near-term operational resilience with long-term strategic advantage. First, fortify supply-chain resilience through diversified sourcing, dual-sourcing strategies, and rigorous supplier quality audits to mitigate tariff and trade disruptions. Second, integrate diagnostic-enabled use cases into product development and commercial positioning to support targeted therapy, reduce inappropriate usage, and strengthen stewardship claims that resonate with regulators and purchasers. Third, invest in evidence generation that goes beyond registration trials to include real-world effectiveness studies, resistance surveillance, and pharmacovigilance that collectively substantiate long-term safety and value.

Moreover, leaders should explore formulation and delivery innovations that improve dosing compliance and reduce environmental exposure, particularly for aquaculture and intensive livestock settings. Digital tools-ranging from telemedicine-enabled prescribing support to mobile dosing calculators-can enhance adherence and provide channels for education and post-market data collection. Finally, adopt adaptive pricing and contracting approaches that recognize regional affordability constraints while preserving margins for reinvestment in R&D. By combining operational rigor, clinical evidence, and customer-centric commercial models, companies can better navigate regulatory expectations and sustain competitive differentiation.

Transparent explanation of the multi-source research methodology combining expert input, regulatory review, and scenario analysis to ensure robust, validated conclusions

The research methodology underpinning this analysis combines qualitative expert interviews, secondary literature review, and structured synthesis of regulatory guidance and public-domain clinical evidence. Primary inputs included consultations with veterinarians, regulatory specialists, manufacturing and supply-chain executives, and distribution partners to capture operational realities and decision criteria across species and channels. Secondary sources encompassed peer-reviewed literature on antimicrobial resistance, regulatory agency guidance documents, and industry publications to ensure alignment with accepted clinical and policy frameworks.

Analysis followed a triangulated approach: thematic coding of qualitative inputs informed segmentation insights and competitive assessments, while regulatory and clinical documents anchored interpretations of stewardship and safety constraints. Scenario analysis was employed to explore the operational implications of trade and tariff changes on supply chains and pricing dynamics, with particular attention to pathways that preserve access and quality. Throughout the process, efforts were made to validate findings against multiple sources and to surface uncertainties explicitly, ensuring that recommendations are grounded in robust evidence and informed judgment.

Final synthesis emphasizing the need for integrated strategies across stewardship, supply resilience, evidence generation, and tailored commercial approaches

In conclusion, the veterinary anti-infectives landscape is being reshaped by a convergence of scientific, regulatory, and commercial forces that require integrated responses from industry stakeholders. Antimicrobial stewardship imperatives and diagnostic advances are redirecting product development toward precision use and robust evidence generation, while policy shifts and tariffs are prompting more resilient supply-chain designs. Segmentation across product types, routes of administration, animal types, distribution channels, and application contexts underscores that one-size-fits-all strategies are no longer sufficient; rather, tailored approaches that address species-specific needs, regional regulatory nuance, and channel-specific dynamics are essential.

Forward-looking organizations will prioritize investments that support responsible use, demonstrate clinical and economic value, and enhance operational flexibility. By aligning R&D priorities with stewardship expectations, strengthening supply-chain resilience, and leveraging digital and diagnostic enablers, companies can both meet immediate market demands and build sustainable competitive advantage. The path forward demands coordination across scientific, regulatory, and commercial functions to translate insights into actionable programs that secure access to effective therapies while safeguarding animal and public health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Anti-infectives Market, by Product Type

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta Lactams
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Sulfonamides
    • 8.1.6. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Polyenes
  • 8.3. Antiparasitics
    • 8.3.1. Acaricides
    • 8.3.2. Anthelmintics
    • 8.3.3. Insecticides

9. Veterinary Anti-infectives Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Pellets
    • 9.2.2. Powders
    • 9.2.3. Suspensions
    • 9.2.4. Tablets
  • 9.3. Topical
    • 9.3.1. Creams
    • 9.3.2. Dips
    • 9.3.3. Ointments
    • 9.3.4. Sprays

10. Veterinary Anti-infectives Market, by Animal Type

  • 10.1. Aquaculture
    • 10.1.1. Fish
    • 10.1.2. Shrimp
  • 10.2. Companion Animal
    • 10.2.1. Cats
    • 10.2.2. Dogs
  • 10.3. Livestock
    • 10.3.1. Cattle
    • 10.3.2. Goats
    • 10.3.3. Sheep
    • 10.3.4. Swine
  • 10.4. Poultry
    • 10.4.1. Chicken
    • 10.4.2. Turkey

11. Veterinary Anti-infectives Market, by Distribution Channel

  • 11.1. Online Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Clinics
  • 11.4. Veterinary Hospitals

12. Veterinary Anti-infectives Market, by Application

  • 12.1. Prophylactic
  • 12.2. Therapeutic

13. Veterinary Anti-infectives Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Anti-infectives Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Anti-infectives Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Veterinary Anti-infectives Market

17. China Veterinary Anti-infectives Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Ashish Life Science Private Limited
  • 18.6. Bimeda Inc.
  • 18.7. Biogenesis Bago S.A.
  • 18.8. C.H. Boehringer Sohn AG & Co. KG
  • 18.9. Ceva Sante Animale
  • 18.10. Dechra Pharmaceuticals PLC
  • 18.11. Eco Animal Health Group PLC
  • 18.12. Elanco Animal Health Incorporated
  • 18.13. Intas Pharmaceuticals Ltd.
  • 18.14. Krka, d. d., Novo mesto
  • 18.15. Kyoritsuseiyaku Corporation
  • 18.16. LABORATORIO AVI-MEX
  • 18.17. LABORATORIOS CALIER, S.A.
  • 18.18. Merck KGaA
  • 18.19. Neogen Corporation
  • 18.20. Ourofino Group
  • 18.21. Sequent Scientific Ltd.
  • 18.22. Vetoquinol SA
  • 18.23. Virbac SA
  • 18.24. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY ANTI-INFECTIVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VETERINARY ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VETERINARY ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. GCC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 308. GCC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. GCC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 310. GCC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 311. GCC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 312. GCC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 313. GCC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 201